Analyst cuts regeneron pharmaceuticals (regn) price target after sales concerns and investor lawsuit– hagens berman

San francisco, feb. 14, 2025 (globe newswire) -- regeneron pharmaceuticals, inc. (nasdaq: regn) is facing mounting pressure on multiple fronts. following disappointing sales figures and ongoing legal challenges, analysts td cowen recently lowered its price target for regeneron to $1,030 from $1,230.
REGN Ratings Summary
REGN Quant Ranking